A Single-center Cross-sectional Study to Evaluate the Effectiveness of Antihypertensive Treatment Including Fimasartan and the Dyslipidemia Treatment Including Rosuvastatin and to Assess the Association Between the Two Treatments
Phase of Trial: Phase IV
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Fimasartan (Primary) ; Rosuvastatin (Primary)
- Indications Dyslipidaemias; Hypertension
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms FIMARO
- Sponsors Boryung Pharmaceutical
- 25 Jul 2017 Planned End Date changed from 1 Apr 2017 to 30 Mar 2018.
- 25 Jul 2017 Planned primary completion date changed from 1 Feb 2017 to 30 Mar 2018.
- 25 Jul 2017 Status changed from not yet recruiting to recruiting.